L-Carnitine Supplementation for the Management of Fatigue in Patients With Cancer: An Eastern Cooperative Oncology Group Phase III, Randomized, Double-Blind, Placebo-Controlled Trial

Ricardo A. Cruciani, Beth Israel Medical Center, New York, and Albert Einstein College of Medicine, Bronx, NY
Journal of Clinical Oncology (Impact Factor: 18.43). 09/2012; 30(31). DOI: 10.1200/JCO.2011.40.2180
Source: PubMed


PURPOSEL-carnitine, a popular complementary and alternative medicine product, is used by patients with cancer for the treatment of fatigue, the most commonly reported symptom in this patient population. The purpose of this study was to determine the efficacy of L-carnitine supplementation as a treatment for fatigue in patients with cancer. PATIENTS AND METHODS
In this double-blind, placebo-controlled trial, patients with invasive malignancies and fatigue were randomly assigned to either 2 g/d of L-carnitine oral supplementation or matching placebo. The primary end point was the change in average daily fatigue from baseline to week 4 using the Brief Fatigue Inventory (BFI). RESULTS: -0.96, 95% CI, -1.32 to -0.60; placebo: -1.11, 95% CI -1.44 to -0.78). There were no statistically significant differences between arms (P = .57). Secondary outcomes, including fatigue measured by the Functional Assessment of Chronic Illness Therapy-Fatigue instrument, depression, and pain, did not show significant difference between arms. A separate analysis of patients who were carnitine-deficient at baseline did not show statistically significant improvement in fatigue or other outcomes after L-carnitine supplementation. CONCLUSION
Four weeks of 2 g of L-carnitine supplementation did not improve fatigue in patients with invasive malignancies and good performance status.

Full-text preview

Available from:
  • Source
    • "Intravenous L-carnitine treatment improved patient-assessed fatigue in patients undergoing hemodialysis [3]. However, L-carnitine supplementation to treat carnitine deficiency did not improve fatigue in patients with invasive malignancies and good performance status [4]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: L-carnitine is an important metabolic mediator involved in fatty acid transport. It is obtained from the diet, particularly from animal products, such as red meat. Previous reports have revealed that long-term tube feeding with a commercial product containing no or low levels of carnitine can lead to an altered mental state caused by hyperammonemia. A 72-year-old Japanese man had a 12-year history of amyotrophic lateral sclerosis. He was bedridden and had required mechanical ventilation and enteral tube feeding for 10 years at home. His main enteral solution was a commercial product that contained low carnitine levels, and he sometimes received coffee and homemade products such as miso soup. Our patient's ability to communicate gradually deteriorated over a period of one year. His serum total carnitine level was abnormally low, at 26.7mumol/L (normal range, 45 to 91mumol/L), but his ammonium level was normal. His mental state improved dramatically after starting L-carnitine supplementation (600mg twice daily). This case highlights the importance of avoiding carnitine deficiency in patients with amyotrophic lateral sclerosis undergoing long-term tube feeding. These patients experience progressive muscle atrophy that might cause impaired carnitine storage and might manifest as communication difficulties. Carnitine deficiency can be misdiagnosed as a progression of systemic muscle atrophy. Clinicians should be aware of this disorder and should consider periodically measuring carnitine levels, regardless of the patient's serum ammonium levels.
    Journal of Medical Case Reports 12/2013; 7(1):286. DOI:10.1186/1752-1947-7-286

  • Der Onkologe 01/2013; 19(10). DOI:10.1007/s00761-013-2545-6 · 0.14 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Complementary and integrative medicine (CIM) is defined by the National Institutes of Health as a group of diverse medical and health care systems, practices, and products not generally considered part of conventional medicine. CIM practices are grouped into 4 categories: natural products, mind and body medicine practices, manipulative practices, and body-based practices. CIM use in patients is common and a working knowledge is relevant to practicing physicians. This article presents an overview of common forms of CIM and their theoretic framework to review the data regarding CIM use in thyroid disease. The intent is to facilitate communication between patients and physicians regarding CIM.
    Otolaryngologic Clinics of North America 06/2013; 46(3):423-35. DOI:10.1016/j.otc.2013.02.004 · 1.49 Impact Factor
Show more